Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Targeting ZNF410 as a potential β-hemoglobinopathy therapy

The nucleosome remodeling and deacetylase (NuRD) complex is a chromatin modifier with a key role in the switch from fetal to adult hemoglobin. In a new study, Vinjamur et al. identify a fetal hemoglobin repressor, ZNF410, which does not directly bind the γ-globin promoter but acts through highly specific regulation of CHD4, a protein subunit of the NuRD complex, thus presenting a potential approach for therapeutic reactivation of fetal hemoglobin.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: ZNF410 transactivation of CHD4 through 27 evolutionarily conserved DNA-binding motifs.


  1. 1.

    Piel, F. B., Steinberg, M. H. & Rees, D. C. N. Engl. J. Med. 376, 1561–1573 (2017).

    CAS  Article  Google Scholar 

  2. 2.

    Williams, T. N. & Thein, S. L. Annu. Rev. Genomics Hum. Genet. 19, 113–147 (2018).

    CAS  Article  Google Scholar 

  3. 3.

    Orkin, S. H. & Bauer, D. E. Annu. Rev. Med. 70, 257–271 (2019).

    CAS  Article  Google Scholar 

  4. 4.

    Menzel, S. et al. Nat. Genet. 39, 1197–1199 (2007).

    CAS  Article  Google Scholar 

  5. 5.

    Masuda, T. et al. Science 351, 285–289 (2016).

    CAS  Article  Google Scholar 

  6. 6.

    Liu, N. et al. Cell 173, 430–442.e17 (2018).

    CAS  Article  Google Scholar 

  7. 7.

    Martyn, G. E. et al. Nat. Genet. 50, 498–503 (2018).

    CAS  Article  Google Scholar 

  8. 8.

    Esrick, E. B. et al. N. Engl. J. Med. 384, 205–215 (2021).

    CAS  Article  Google Scholar 

  9. 9.

    Frangoul, H. et al. N. Engl. J. Med. 384, 252–260 (2021).

    CAS  Article  Google Scholar 

  10. 10.

    Tisdale, J. F., Thein, S. L. & Eaton, W. A. Science 367, 1198–1199 (2020).

    CAS  Article  Google Scholar 

  11. 11.

    Molokie, R. et al. PLoS Med. 14, e1002382 (2017).

    Article  Google Scholar 

  12. 12.

    Millard, C. J. et al. eLife 5, e13941 (2016).

    Article  Google Scholar 

  13. 13.

    Sher, F. et al. Nat. Genet. 51, 1149–1159 (2019).

    CAS  Article  Google Scholar 

  14. 14.

    Shearstone, J. R. et al. PLoS ONE 11, e0153767 (2016).

    Article  Google Scholar 

  15. 15.

    Vinjamur, D. S. Nat. Genet. (2021).

  16. 16.

    Lan, X. et al. Mol. Cell 81, 239–254.e8 (2021).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Swee Lay Thein.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tumburu, L., Thein, S.L. Targeting ZNF410 as a potential β-hemoglobinopathy therapy. Nat Genet 53, 589–590 (2021).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing